Genfit 
Welcome,         Profile    Billing    Logout  
 2 Products   26 Diseases  2 Products   11 Trials   574 News 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iqirvo (elafibranor) / Ipsen
ELATIVE, NCT04526665 / 2019-004941-34: Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Active, not recruiting
3
161
Europe, Canada, US, RoW
Elafibranor 80mg, Iqirvo®, Placebo
Ipsen
Primary Biliary Cirrhosis
06/23
12/28
ELSPIRE, NCT06383403: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Recruiting
3
72
Europe, US, RoW
Elafibranor, IPN60190, Placebo
Ipsen
Primary Biliary Cholangitis
10/26
10/26
ELONSEN, NCT06730061: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

Recruiting
3
18
Japan
Elafibranor
Ipsen
Primary Biliary Cholangitis
03/26
04/32
ELFIDENCE, NCT06016842: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Recruiting
3
276
Europe, Canada, US, RoW
Elafibranor, Matched 80 mg placebo
Ipsen
Primary Biliary Cholangitis (PBC)
05/29
05/29
2010-023219-32: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety in patients with insulin resistance and abdominal obesity.A Multicentre, Randomised, Single Blind, Placebo-Controlled, cross over study.

Not yet recruiting
2
20
Europe
GFT505 20mg lactose - magnesium stearate, GFT505, Capsule, hard
GENFIT
Patients with insulin resistance and abdominal obesity
 
 
2007-003237-16: A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.

Ongoing
2
30
Europe
GFT505, GFT505,
GENFIT
Patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia).
 
 
2007-004337-41: A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.

Ongoing
2
30
Europe
GFT505, GFT505,
GENFIT
Atherogenic dyslipidaemic patients with abdominal obesity
 
 
2019-000645-12: Clinical study to assess the effect of a 6-week Elafibranor (120mg) treatment administered once daily on liver fat composition in subjects with Nonalcoholic Fatty Liver (NAFL).

Not yet recruiting
2
16
Europe
elafibranor, GFT505, Coated tablet
GENFIT SA, GENFIT
Subjects with Nonalcoholic Fatty Liver (NAFL), Non-Alcoholic Fatty Liver (NAFL)., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2022-002695-37: A study on safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Estudio sobre la seguridad y la eficacia del elafibranor en participantes adultos con colangitis esclerosante primaria (CEP)

Ongoing
2
60
Europe
IPN60190; GFT505, Tablet
Ipsen Bioscience, Inc., Ipsen Bioscience, Inc.
Adults patients with Primary Sclerosing Cholangitis (PSC) Pacientes adultos con colangitis esclerosante primaria (CEP), Primary Sclerosing Cholangitis (PSC) is a progressive liver disease characterised by inflammation and fibrosis of the bile ducts with risk of liver failure. La colangitis esclerosante primaria (CEP) es una enfermedad hepática progresiva caracterizada por inflamación y fibrosis de los conductos biliares, con riesgo de insuficiencia hepática., Body processes [G] - Metabolic Phenomena [G03]
 
 
ELMWOOD, NCT05627362 / 2022-002695-37: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

Active, not recruiting
2
68
Europe, Canada, US
Elafibranor 80 mg, GFT505, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
Ipsen, Ipsen Bioscience, Inc.
Primary Sclerosing Cholangitis
08/26
08/26
2022-001883-91: A Study to Evaluate Effects of Food on the Bioavailability of Elafibranor in Healthy Subjects.

Not yet recruiting
1
34
Europe
Elafibranor, IPN60190, Film-coated tablet
Ipsen Bioscience Inc, Ipsen Bioscience Inc
This is a study to evaluate the effects of food on the bioavailability of elafibranor in healthy adult participants. It is part of a clinical development program for the IMP, the intended indication of which is for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA., This study assesses the effects of food on the effectiveness of elafibranor in healthy adults. It is part of a program to treat adult patients with a liver disease called primary biliary cholangitis., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05543369: Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Completed
1
48
US
Elafibranor, GFT505
Ipsen
Healthy Volunteers
03/23
03/23
ELFINITY, NCT06447168: A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Recruiting
N/A
424
Europe, Canada, US
Ipsen
Primary Biliary Cholangitis
07/32
07/32
ezurpimtrostat (GNS561) / Genoscience Pharma, Genfit
CureCovid-2019, NCT04637828 / 2020-002249-40: A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Recruiting
2
178
Europe
GNS561
Genoscience Pharma, Genoscience Pharma
COVID-19
07/21
12/21
ABE-LIVER, NCT05448677: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Terminated
2
3
Europe
Ezurpimtrostat, Atezolizumab, Bevacizumab
University Hospital, Grenoble, Genoscience Pharma
Hepatocellular Carcinoma
03/24
03/24
NCT05874414: Combination of GNS561 and Trametinib in Patients with Advanced KRAS Mutated Cholangiocarcinoma

Recruiting
1/2
74
US
GNS561 + Trametinib, Ezurpimtrostat (GNS561)
Genfit
Cholangiocarcinoma
05/26
10/26
NCT05353894: Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers

Not yet recruiting
1
27
Europe
GNS561 oral tablets and capsules
Genoscience Pharma
Primary Liver Cancer
11/22
11/22
Inhaled RORγt drug candidate / Genfit
No trials found
Topical RORγt drug candidate / Genfit
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iqirvo (elafibranor) / Ipsen
ELATIVE, NCT04526665 / 2019-004941-34: Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Active, not recruiting
3
161
Europe, Canada, US, RoW
Elafibranor 80mg, Iqirvo®, Placebo
Ipsen
Primary Biliary Cirrhosis
06/23
12/28
ELSPIRE, NCT06383403: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Recruiting
3
72
Europe, US, RoW
Elafibranor, IPN60190, Placebo
Ipsen
Primary Biliary Cholangitis
10/26
10/26
ELONSEN, NCT06730061: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

Recruiting
3
18
Japan
Elafibranor
Ipsen
Primary Biliary Cholangitis
03/26
04/32
ELFIDENCE, NCT06016842: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Recruiting
3
276
Europe, Canada, US, RoW
Elafibranor, Matched 80 mg placebo
Ipsen
Primary Biliary Cholangitis (PBC)
05/29
05/29
2010-023219-32: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety in patients with insulin resistance and abdominal obesity.A Multicentre, Randomised, Single Blind, Placebo-Controlled, cross over study.

Not yet recruiting
2
20
Europe
GFT505 20mg lactose - magnesium stearate, GFT505, Capsule, hard
GENFIT
Patients with insulin resistance and abdominal obesity
 
 
2007-003237-16: A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.

Ongoing
2
30
Europe
GFT505, GFT505,
GENFIT
Patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia).
 
 
2007-004337-41: A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.

Ongoing
2
30
Europe
GFT505, GFT505,
GENFIT
Atherogenic dyslipidaemic patients with abdominal obesity
 
 
2019-000645-12: Clinical study to assess the effect of a 6-week Elafibranor (120mg) treatment administered once daily on liver fat composition in subjects with Nonalcoholic Fatty Liver (NAFL).

Not yet recruiting
2
16
Europe
elafibranor, GFT505, Coated tablet
GENFIT SA, GENFIT
Subjects with Nonalcoholic Fatty Liver (NAFL), Non-Alcoholic Fatty Liver (NAFL)., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2022-002695-37: A study on safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Estudio sobre la seguridad y la eficacia del elafibranor en participantes adultos con colangitis esclerosante primaria (CEP)

Ongoing
2
60
Europe
IPN60190; GFT505, Tablet
Ipsen Bioscience, Inc., Ipsen Bioscience, Inc.
Adults patients with Primary Sclerosing Cholangitis (PSC) Pacientes adultos con colangitis esclerosante primaria (CEP), Primary Sclerosing Cholangitis (PSC) is a progressive liver disease characterised by inflammation and fibrosis of the bile ducts with risk of liver failure. La colangitis esclerosante primaria (CEP) es una enfermedad hepática progresiva caracterizada por inflamación y fibrosis de los conductos biliares, con riesgo de insuficiencia hepática., Body processes [G] - Metabolic Phenomena [G03]
 
 
ELMWOOD, NCT05627362 / 2022-002695-37: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

Active, not recruiting
2
68
Europe, Canada, US
Elafibranor 80 mg, GFT505, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
Ipsen, Ipsen Bioscience, Inc.
Primary Sclerosing Cholangitis
08/26
08/26
2022-001883-91: A Study to Evaluate Effects of Food on the Bioavailability of Elafibranor in Healthy Subjects.

Not yet recruiting
1
34
Europe
Elafibranor, IPN60190, Film-coated tablet
Ipsen Bioscience Inc, Ipsen Bioscience Inc
This is a study to evaluate the effects of food on the bioavailability of elafibranor in healthy adult participants. It is part of a clinical development program for the IMP, the intended indication of which is for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA., This study assesses the effects of food on the effectiveness of elafibranor in healthy adults. It is part of a program to treat adult patients with a liver disease called primary biliary cholangitis., Diseases [C] - Immune System Diseases [C20]
 
 
NCT05543369: Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Completed
1
48
US
Elafibranor, GFT505
Ipsen
Healthy Volunteers
03/23
03/23
ELFINITY, NCT06447168: A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Recruiting
N/A
424
Europe, Canada, US
Ipsen
Primary Biliary Cholangitis
07/32
07/32
ezurpimtrostat (GNS561) / Genoscience Pharma, Genfit
CureCovid-2019, NCT04637828 / 2020-002249-40: A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection

Recruiting
2
178
Europe
GNS561
Genoscience Pharma, Genoscience Pharma
COVID-19
07/21
12/21
ABE-LIVER, NCT05448677: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Terminated
2
3
Europe
Ezurpimtrostat, Atezolizumab, Bevacizumab
University Hospital, Grenoble, Genoscience Pharma
Hepatocellular Carcinoma
03/24
03/24
NCT05874414: Combination of GNS561 and Trametinib in Patients with Advanced KRAS Mutated Cholangiocarcinoma

Recruiting
1/2
74
US
GNS561 + Trametinib, Ezurpimtrostat (GNS561)
Genfit
Cholangiocarcinoma
05/26
10/26
NCT05353894: Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers

Not yet recruiting
1
27
Europe
GNS561 oral tablets and capsules
Genoscience Pharma
Primary Liver Cancer
11/22
11/22
Inhaled RORγt drug candidate / Genfit
No trials found
Topical RORγt drug candidate / Genfit
No trials found

Download Options